Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial
Launched by SAFFRON PHARMA · Nov 27, 2022
Trial Information
Current as of January 16, 2025
Completed
Keywords
ClinConnect Summary
Background Seasonal and perennial allergic rhinitis, acute rhino sinusitis, and nasal polyposis are examples of common inflammatory disorders of the airway that significantly reduce patient health and quality of life. Intranasal corticosteroids are advised as part of treatment plans for each of these illnesses since they help to reduce inflammation and thus symptoms.
Objective In order to assess the effectiveness and safety of a new nano formulation of Mometasone furoate nano-nasal spray (FM-NNS) for the treatment of allergic rhinitis. Mometasone Furoate Nano-nasal spray (FM-NNS) was compa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Children and adults of age (10-50) who had a diagnosis of rhinitis
- • 2. Ability and willingness to understand and provide informed consent.
- Exclusion Criteria:
- • 1. Known current pregnancy.
- • 2. Current hospitalization.
- • 3. Unable to complete online questionnaires or adhere to study requirements.
- • 4. Kidney failure or dialysis; severe liver disease or cirrhosis.
- • 5. Any parathyroid conditions.
- • 6. Known current pregnancy.
- • 7. History of SARS-CoV-2 infection.
About Saffron Pharma
Saffron Pharma is a forward-thinking clinical trial sponsor dedicated to advancing innovative therapies that address unmet medical needs. With a commitment to rigorous scientific research and ethical standards, Saffron Pharma specializes in the development and management of clinical trials across various therapeutic areas. The organization leverages a collaborative approach, working closely with healthcare professionals, regulatory bodies, and research institutions to ensure the successful execution of trials. By prioritizing patient safety and data integrity, Saffron Pharma aims to contribute to the enhancement of global health outcomes through the discovery and delivery of effective pharmaceutical solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Faisalabad, Punjab, Pakistan
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials